SCHEMBL358973

SCHEMBL358973

COc1cccc(OC)c1N

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.59
TDP1 Q9NUW8 2/20 0.59
ADRA2B P18089 1/20 0.59
PTGS1 P23219 1/20 0.59
CA1 P00915 4/20 0.58
CA2 P00918 4/20 0.58
CA7 P43166 3/20 0.58
CA9 Q16790 3/20 0.58
CA12 O43570 2/20 0.58
CA14 Q9ULX7 2/20 0.58
CA4 P22748 1/20 0.58
MAPK1 P28482 3/20 0.50
CYP3A4 P08684 3/20 0.50
TP53 P04637 2/20 0.50
KDM4E B2RXH2 2/20 0.50
MAPT P10636 2/20 0.50
LMNA P02545 1/20 0.50
HPGD P15428 1/20 0.50
ALOX15 P16050 1/20 0.50
ALOX12 P18054 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Nitrogen SCHEMBL27853237 0.95 ALDH1A1 (0.54) ALDH1A1TDP1ADRA2BPTGS1CA1
Aniline SCHEMBL22169132 0.88 ALDH1A1 (0.54) ALDH1A1TDP1ADRA2BPTGS1CA1
SCHEMBL216473 0.87 ALDH1A1 (0.65) ALDH1A1TDP1ADRA2BPTGS1CA1
SCHEMBL2212731 0.87 ALDH1A1 (0.52) ALDH1A1TDP1ADRA2BPTGS1CA1
SCHEMBL29726496 0.87 ALDH1A1 (0.65) ALDH1A1TDP1ADRA2BPTGS1CA1
SCHEMBL31607623 0.87 ALDH1A1 (0.52) ALDH1A1TDP1ADRA2BPTGS1CA1
Hydrochloric Acid SCHEMBL3879296 0.85 ALDH1A1 (0.62) ALDH1A1TDP1ADRA2BPTGS1CA1
SCHEMBL3293006 0.85 ALDH1A1 (0.50) ALDH1A1TDP1ADRA2BPTGS1CA1
SCHEMBL29486564 0.85 CD44 (0.52) ALDH1A1TDP1ADRA2BPTGS1CA1
SCHEMBL288824 0.85 CD44 (0.52) ALDH1A1TDP1ADRA2BPTGS1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 678 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120081790-A Bridged double-center carbene catalyst ligand and preparation method and application thereof 上海化工研究院有限公司 2025-06-03 CN claimed
CN-118324654-A Visible light responsive azobenzene amphiphilic small molecule and preparation method thereof 太原师范学院 2024-07-12 CN claimed
CN-116854601-A Novel method for preparing 4-diaryl methyl substituted aniline compound by mediation of hexafluoroisopropanol 湖南理工学院 2023-10-10 CN claimed
CN-115260690-B Super-molecular hydrogel with visible light response and preparation method and application thereof 复旦大学 2023-05-30 CN claimed
CN-115397824-A Process for preparing COT inhibitor compounds 吉利德科学公司 2022-11-25 CN claimed
CN-115260690-A Visible light response supramolecular hydrogel and preparation method and application thereof 复旦大学 2022-11-01 CN claimed
CN-114276371-A Boron-oxygen doped fused ring aromatic hydrocarbon containing pyrrole ring and synthesis method and application thereof 天津理工大学 2022-04-05 CN claimed
CN-113583262-B Near-infrared response hyaluronic acid hydrogel for articular cartilage repair and preparation method thereof 四川大学 2022-03-29 CN claimed
CN-113583262-A Near-infrared response hyaluronic acid hydrogel for articular cartilage repair and preparation method thereof 四川大学 2021-11-02 CN claimed
CN-111518297-A Preparation method of visible light stimulus responsive polyacrylamide supramolecular film 华东师范大学 2020-08-11 CN claimed
US-20100113791-A1 PREPARATION OF PRECURSORS OF CARBENES OF CAAC TYPE AND PREPARING SAID CARBENES THEREFROM RHODIA OPERATIONS (FR) 2010-05-06 US claimed
EP-2139853-A1 PROCESS FOR PREPARING PRECURSORS OF CARBENES OF CAAC TYPE AND USE THEREOF FOR PREPARING SAID CARBENES Rhodia Opérations (FR) 2010-01-06 EP claimed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US claimed
EP-2074089-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2009-07-01 EP claimed
EP-2065380-A1 Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer F.HOFFMANN-LA ROCHE AG (CH) 2009-06-03 EP claimed
WO-2009024332-A1 PYRIDONEAMIDE DERIVATIVES AS FOCAL ADHESION KINASE (FAK) INHIBITORS AND THEIR USE FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2009-02-26 WO claimed
WO-2008125568-A1 PROCESS FOR PREPARING PRECURSORS OF CARBENES OF CAAC TYPE AND USE THEREOF FOR PREPARING SAID CARBENES RHODIA OPERATIONS (FR) 2008-10-23 WO claimed
WO-2008048991-A2 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2008-04-24 WO claimed
CN-1405631-A Self-sensitizing type super-branched polyimide photo-sensitive material and its preparing method UNIV SHANGHAI JIAOTONG (CN) 2003-03-26 CN claimed
EP-0070130-A1 Improvement in or relating to benzoylphenyl urea derivatives ELI LILLY AND COMPANY (US) 1983-01-19 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227583-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2B ALDH1A1 2403/4885TDP1 2319/4885ADRA2B 38/4885
US-20100113791-A1 PREPARATION OF PRECURSORS OF CARBENES OF CAAC TYPE AND PREPARING SAID CARBENES THEREFROM CCNC, HCCS, CYCS ALDH1A1 2543/4885TDP1 3155/4885ADRA2B 2508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.